148 related articles for article (PubMed ID: 10652791)
1. [Molecular modeling studies of prolyl endopeptidase inhibitors].
Kánai K; Fehér M; Lopata A; Podányi B; Novák I; Susán E; Hermecz I; Arányi P
Acta Pharm Hung; 1999 Nov; 69(5):240-6. PubMed ID: 10652791
[TBL] [Abstract][Full Text] [Related]
2. [Prolyl endopeptidase inhibitors].
Aoyagi T; Muraoka Y
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1971-86. PubMed ID: 8210438
[No Abstract] [Full Text] [Related]
3. An integrated approach to ligand- and structure-based drug design: development and application to a series of serine protease inhibitors.
Nicolotti O; Miscioscia TF; Carotti A; Leonetti F; Carotti A
J Chem Inf Model; 2008 Jun; 48(6):1211-26. PubMed ID: 18540590
[TBL] [Abstract][Full Text] [Related]
4. Novel inhibitors of prolyl endopeptidase: effects of stereochemistry.
Kolosko N; Bakker AV; Faraci WS; Nagel AA
Drug Des Discov; 1994 Jan; 11(1):61-71. PubMed ID: 8068820
[TBL] [Abstract][Full Text] [Related]
5. Suggested functions for prolyl oligopeptidase: a puzzling paradox.
Brandt I; Scharpé S; Lambeir AM
Clin Chim Acta; 2007 Feb; 377(1-2):50-61. PubMed ID: 17034776
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of prolyl endopeptidase: characterization of the pharmacophoric pattern using conformational analysis and 3D-QSAR.
Langer T; Wermuth CG
J Comput Aided Mol Des; 1993 Jun; 7(3):253-62. PubMed ID: 8377023
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Bhongade BA; Gouripur VV; Gadad AK
Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
[TBL] [Abstract][Full Text] [Related]
8. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
[TBL] [Abstract][Full Text] [Related]
9. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.
Jarho EM; Venäläinen JI; Huuskonen J; Christiaans JA; Garcia-Horsman JA; Forsberg MM; Järvinen T; Gynther J; Männistö PT; Wallén EA
J Med Chem; 2004 Nov; 47(23):5605-7. PubMed ID: 15509157
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G.
Maryanoff BE
J Med Chem; 2004 Feb; 47(4):769-87. PubMed ID: 14761180
[No Abstract] [Full Text] [Related]
11. The relationship between inhibitors of eukaryotic and prokaryotic serine proteases.
Konaklieva MI; Plotkin BJ
Mini Rev Med Chem; 2004 Sep; 4(7):721-39. PubMed ID: 15379640
[TBL] [Abstract][Full Text] [Related]
12. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
[TBL] [Abstract][Full Text] [Related]
14. Sulfated chitooligosaccharides as prolyl endopeptidase inhibitor.
Je JY; Kim EK; Ahn CB; Moon SH; Jeon BT; Kim B; Park TK; Park PJ
Int J Biol Macromol; 2007 Dec; 41(5):529-33. PubMed ID: 17714777
[TBL] [Abstract][Full Text] [Related]
15. Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules.
Kánai K; Arányi P; Böcskei Z; Ferenczy G; Harmat V; Simon K; Bátori S; Náray-Szabo G; Hermecz I
J Med Chem; 2008 Dec; 51(23):7514-22. PubMed ID: 19006380
[TBL] [Abstract][Full Text] [Related]
16. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
[TBL] [Abstract][Full Text] [Related]
17. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
[TBL] [Abstract][Full Text] [Related]
18. Structure-guided design of peptide-based tryptase inhibitors.
McGrath ME; Sprengeler PA; Hirschbein B; Somoza JR; Lehoux I; Janc JW; Gjerstad E; Graupe M; Estiarte A; Venkataramani C; Liu Y; Yee R; Ho JD; Green MJ; Lee CS; Liu L; Tai V; Spencer J; Sperandio D; Katz BA
Biochemistry; 2006 May; 45(19):5964-73. PubMed ID: 16681368
[TBL] [Abstract][Full Text] [Related]
19. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.
Miyazaki Y; Kato Y; Manabe T; Shimada H; Mizuno M; Egusa T; Ohkouchi M; Shiromizu I; Matsusue T; Yamamoto I
Bioorg Med Chem Lett; 2006 Jun; 16(11):2986-90. PubMed ID: 16540315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
